Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals European Union - English - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.

Adartrel 500microgram tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

adartrel 500microgram tablets

glaxosmithkline uk ltd - ropinirole hydrochloride - oral tablet - 500microgram

Adartrel 250microgram tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

adartrel 250microgram tablets

glaxosmithkline uk ltd - ropinirole hydrochloride - oral tablet - 250microgram

Adartrel 2mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

adartrel 2mg tablets

glaxosmithkline uk ltd - ropinirole hydrochloride - oral tablet - 2mg

Motens 2mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

motens 2mg tablets

glaxosmithkline uk ltd - lacidipine - oral tablet - 2mg

Motens 4mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

motens 4mg tablets

glaxosmithkline uk ltd - lacidipine - oral tablet - 4mg

Fortum New Zealand - English - Medsafe (Medicines Safety Authority)

fortum

glaxosmithkline nz limited - ceftazidime pentahydrate 1 g - powder for injection - 1 g - active: ceftazidime pentahydrate 1 g excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

Fortum New Zealand - English - Medsafe (Medicines Safety Authority)

fortum

glaxosmithkline nz limited - ceftazidime pentahydrate 2 g - powder for injection - 2 g - active: ceftazidime pentahydrate 2 g excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

Fortum New Zealand - English - Medsafe (Medicines Safety Authority)

fortum

glaxosmithkline nz limited - ceftazidime pentahydrate 500mg - powder for injection - 500 mg - active: ceftazidime pentahydrate 500mg excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

Zinacef New Zealand - English - Medsafe (Medicines Safety Authority)

zinacef

glaxosmithkline nz limited - cefuroxime sodium 262.5mg equivalent to 250 mg cefuroxime - powder for injection - 250 mg - active: cefuroxime sodium 262.5mg equivalent to 250 mg cefuroxime